Share This Page
Drug Price Trends for NDC 57896-0791
✉ Email this page to a colleague
Average Pharmacy Cost for 57896-0791
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 57896-0791
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| GAS RELIEF | Geri-Care Pharmaceutical Corp | 57896-0791-01 | 100 | 1.65 | 0.01650 | 2022-11-15 - 2026-06-14 | FSS |
| SIMETHICONE 80MG TAB,CHEW | Geri-Care Pharmaceutical Corp | 57896-0791-08 | 8 | 1.05 | 0.13125 | 2023-01-05 - 2026-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC: 57896-0791
Introduction
The pharmaceutical landscape for the drug identified by NDC 57896-0791 is characterized by dynamic market factors, regulatory considerations, and evolving clinical usage. Delivering a comprehensive market analysis and future pricing projections necessitates understanding its therapeutic profile, competitive environment, patent landscape, and reimbursement mechanisms. This analysis synthesizes current market data, industry trends, and pricing strategies to inform stakeholders about the potential trajectory of this drug.
Therapeutic Profile and Clinical Positioning
NDC 57896-0791 corresponds to [Insert Drug Name], a [insert primary indication, e.g., biologic or small molecule, e.g., rheumatoid arthritis, oncology, metabolic disorders] treatment approved by the FDA in [year]. Its mechanism of action involves [briefly describe mechanism], offering [specific clinical advantage, e.g., superior efficacy, improved safety] over existing therapies.
Clinical trials demonstrate [key efficacy data, e.g., significant symptom reduction, survival benefit], positioning it as a preferred option in [specific patient population]. Off-label uses remain limited, with ongoing research exploring expanded indications, potentially influencing future market size.
Market Size and Penetration
The current global market for [indication] drugs is valued at approximately $X billion in [year], projected to grow at a CAGR of X% through [year], driven by increasing prevalence, diagnosis rates, and treatment adoption.
In the United States, [indication] affects roughly X million patients, with an estimated Y% receiving pharmacologic therapy. NDC 57896-0791 entered the market in [year], initially targeting [specific subset, e.g., moderate to severe cases/elderly population], capturing an approximate X% market share within its first [timeframe].
Key factors influencing market penetration include:
- Physician adoption driven by clinical guidelines and perceived efficacy.
- Insurance coverage and reimbursement policies.
- Pricing strategies and patient co-pay considerations.
- Competitive landscape comprising similar biologics or biosimilars.
Competitive Landscape
The market comprises [number] of approved therapies, including [list or categorize major competitors, e.g., other biologics, oral alternatives]. The entry of biosimilars introduces pricing pressures, with biosimilar versions of similar products available at approximately [X%] lower than originators.
Regulatory developments, such as [new approvals, label expansions], and patent expirations, notably [dates/statistics on patent cliffs], will significantly influence competitive positioning and pricing in the coming years.
Regulatory and Reimbursement Dynamics
Reimbursement outcomes significantly affect market prices. The drug benefits from inclusion in major formularies such as [list of key payers], with negotiated discounts, prior authorization gates, and step therapy protocols.
Recent trends indicate [specific policy changes, e.g., value-based contracting, Medicare Price Negotiation], impacting preferred formulary placement and patient access. These factors will continue to influence net pricing and utilization.
Pricing Strategies and Projections
Current Pricing Landscape
As of [latest available data], the average wholesale price (AWP) for [drug name] is approximately $X per [dose unit/administration], corresponding to an estimated average selling price (ASP) of $Y** after discounts.
Rebate and discounting practices are commonplace, often reducing net prices by [percent], with payers negotiating outcomes based on clinical value and volume.
Future Price Projections (Next 5 Years)
Based on market maturation, patent protections, and competitive pressures, the following projections are anticipated:
- Year 1-2: Stabilization at current price levels, with slight adjustments (±X%) due to inflation and contract renegotiations.
- Year 3-4: Price compression expected owing to biosimilar entry, with discounts expanding by Y%, leading to a potential reduction in net price of $Z.
- Year 5: Further price reductions of up to [X]%, especially if biosimilars or alternative therapies achieve substantial market share.
Overall, [drug name]'s price is projected to decline by approximately [X]% over five years, aligning with typical biologic degradation curves post-patent expiry.
Impact of Biosimilars
Biosimilars targeted at [reference biologic] could introduce price decreases ranging from [X–Y]%, depending on market dynamics and patent litigation outcomes. Their success heavily depends on payer acceptance and physician switching behavior, which remains uncertain until biosimilar approval and market entry.
Regulatory and Policy Risks
Potential policy shifts, such as [price negotiation reforms, importation policies], could exert downward pressure on prices. Conversely, new indications or unmet needs could maintain or elevate pricing levels temporarily.
Key Market Drivers and Challenges
-
Growth Drivers:
- Increasing disease prevalence.
- Clinical guideline endorsements.
- Expanded indications and label expansions.
-
Challenges:
- Market saturation with biosimilars.
- Reimbursement constraints.
- Patent litigation or exclusivity delays.
Concluding Insights
The market for NDC 57896-0791 is poised for gradual consolidation, with initial stabilization likely followed by price compressions influenced by biosimilar competition and reimbursement trends. Stakeholders should anticipate evolving pricing structures, with strategic focus on expanding indications, optimizing payer negotiations, and monitoring regulatory shifts to capitalize on market opportunities.
Key Takeaways
- Market size and growth reflect significant opportunity but face supply-side and demand-side constraints.
- Pricing is expected to decline steadily over five years, primarily due to biosimilar competition and policy reforms.
- Reimbursement strategies will be pivotal, with payers demanding greater value, influencing net prices.
- Patent expirations and biosimilar entries are critical inflection points impacting long-term price trends.
- Clinical adoption and approval expansions can temporarily sustain or elevate price levels, emphasizing the importance of regulatory engagement.
FAQs
1. What factors most significantly impact the pricing trajectory of NDC 57896-0791?
The primary influences include biosimilar competition, patent status, reimbursement policies, clinical adoption rates, and regulatory approvals for new indications.
2. How does biosimilar entry affect the market price of this drug?
Biosimilars typically introduce price elasticity into the market, leading to reductions of approximately 20–30% relative to originator biologics, depending on market acceptance and competitive dynamics.
3. What is the average timeline for patent expiration and biosimilar entry for biologic drugs like this?
Patent protections generally last 12–14 years post-approval, with biosimilars often entering the market within 6–10 years after patent expiration.
4. How do reimbursement policies influence the net price of drugs like NDC 57896-0791?
Reimbursement negotiations, formulary placements, and policy reforms can significantly reduce net prices, as payers seek discounts and value-based arrangements.
5. What strategies can stakeholders adopt to maximize value in this evolving market?
Stakeholders should focus on expanding indications, engaging in value-based contracting, optimizing supply chain efficiencies, and actively participating in payer negotiations to safeguard market share and profitability.
References
- [Insert relevant industry reports, market research studies, and regulatory updates cited in the analysis].
More… ↓
